Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational ProgressGlobeNewsWire • 08/03/23
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial OfficerGlobeNewsWire • 07/19/23
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023GlobeNewsWire • 07/18/23
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell LymphomaGlobeNewsWire • 06/16/23
Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCOGlobeNewsWire • 06/02/23
Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALLGlobeNewsWire • 05/22/23
Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational ProgressGlobeNewsWire • 05/04/23
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCOGlobeNewsWire • 04/27/23
Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution PartnerGlobeNewsWire • 04/27/23
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic AcidsGlobeNewsWire • 04/26/23
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual MeetingGlobeNewsWire • 04/26/23
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023GlobeNewsWire • 04/20/23
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational ProgressGlobeNewsWire • 03/07/23
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023GlobeNewsWire • 02/15/23
Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSsGlobeNewsWire • 12/21/22